DERL3 facilitates the progression of clear cell renal cell carcinoma by promoting epithelial-mesenchymal transition via regulation of the TGFB1 pathway
PLOS One · 2025
DOI: 10.1371/journal.pone.0322172 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Chengtao Niu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Carcinoma, Renal Cell, Kidney Neoplasms, Transforming Growth Factor beta1. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Innovation Technology Project of Higher School in Shandong Province, Postdoctoral Innovation Project of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background
Clear cell renal cell carcinoma (ccRCC) is a highly prevalent malignancy within the urinary system. The intrinsic heterogeneity and resistance to conventional chemotherapy and radiotherapy contribute to the poor prognosis of advanced ccRCC patients. DERL3, part of the Derlin protein family, was first identified for its critical role in endoplasmic reticulum stress. Subsequent studies have revealed its involvement in the progression of multiple tumor types; however, its role in ccRCC remains unclear.
Methods
In this study, we utilized bioinformatics analysis and in vitro experimental approaches to investigate the role of DERL3 expression in the metastasis of renal clear cell carcinoma cells. Additionally, we analyzed the correlation between DERL3 expression and the prognosis of renal clear cell carcinoma patients, while exploring its potential mechanisms of action.
Results
We demonstrate for the first time that DERL3 promotes tumor progression in ccRCC, showing significantly elevated expression, especially in metastatic ccRCC cell lines. Further studies suggest that this overexpression of DERL3 may promote the epithelial-mesenchymal transition in ccRCC by upregulating TGF-β1, thereby enhancing ccRCC metastasis.
Conclusion
In conclusion, our study clarifies the role and potential mechanisms of DERL3 in ccRCC progression, providing promising therapeutic avenues for improving the prognosis of ccRCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
- Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Shandong Xiehe University, Jinan, China.
- Department of Urology, Weihai Municipal Hospital Affiliated to Shandong University, Weihai, China.
- Department of Urology, People's Hospital of Changle County, Weifang, Shandong, China.
ORCID-Profile: Chengtao Niu, Wei He
Förderung
- Youth Innovation Technology Project of Higher School in Shandong Province
- Postdoctoral Innovation Project of Shandong Province
- Natural Science Foundation of Shandong Province
Zitieren
APA
Niu, C., Cui, H., Sun, X., Yang, Y., Jiang, X., Cong, Z., Zhang, Y., Niu, Z., & He, W. (2025). DERL3 facilitates the progression of clear cell renal cell carcinoma by promoting epithelial-mesenchymal transition via regulation of the TGFB1 pathway. PLOS One. https://doi.org/10.1371/journal.pone.0322172
Vancouver
Niu C, Cui H, Sun X, Yang Y, Jiang X, Cong Z, et al. DERL3 facilitates the progression of clear cell renal cell carcinoma by promoting epithelial-mesenchymal transition via regulation of the TGFB1 pathway. PLOS One. 2025. doi:10.1371/journal.pone.0322172
BibTeX
@article{Niu2025,
author = {Niu, Chengtao and Cui, Haodong and Sun, Xintong and Yang, Yuchang and Jiang, Xue and Cong, Zixiang and Zhang, Yiming and Niu, Zhihong and He, Wei},
title = {DERL3 facilitates the progression of clear cell renal cell carcinoma by promoting epithelial-mesenchymal transition via regulation of the TGFB1 pathway},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322172}
}
EUVIMED